{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:07:02Z","timestamp":1788804422464,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Korea Institute of Radiological and Medical Science","award":["50547-2025"],"award-info":[{"award-number":["50547-2025"]}]},{"DOI":"10.13039\/501100008003","name":"Korea Institute of Radiological and Medical Sciences","doi-asserted-by":"publisher","award":["2020R1A2C2102492"],"award-info":[{"award-number":["2020R1A2C2102492"]}],"id":[{"id":"10.13039\/501100008003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12149-025-02117-5","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:17:29Z","timestamp":1760001449000},"page":"1165-1180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical perspective on targeted alpha therapy using 225Ac"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-1659","authenticated-orcid":false,"given":"Ilhan","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"3","key":"2117_CR1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"Collaboration GBoDC","year":"2022","unstructured":"Collaboration GBoDC. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022;8(3):420\u201344.","journal-title":"JAMA Oncol"},{"issue":"Suppl 2","key":"2117_CR2","doi-asserted-by":"crossref","first-page":"263s","DOI":"10.2967\/jnumed.120.254532","volume":"61","author":"WA Weber","year":"2020","unstructured":"Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, et al. The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med. 2020;61(Suppl 2):263s\u201372s.","journal-title":"J Nucl Med"},{"issue":"12","key":"2117_CR3","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.2967\/jnumed.122.264321","volume":"63","author":"K Herrmann","year":"2022","unstructured":"Herrmann K, Giovanella L, Santos A, Gear J, Ozgen Kiratli P, Kurth J, et al. Joint EANM, SNMMI, and IAEA enabling guide: how to set up a theranostics center. J Nucl Med. 2022;63(12):1836\u201343.","journal-title":"J Nucl Med"},{"issue":"12","key":"2117_CR4","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10446","key":"2117_CR5","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet. 2024;403(10446):2807\u201317.","journal-title":"The Lancet"},{"issue":"9","key":"2117_CR6","first-page":"1490","volume":"27","author":"JL Humm","year":"1986","unstructured":"Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986;27(9):1490\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"2117_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0360-3016(01)01585-1","volume":"51","author":"SK Imam","year":"2001","unstructured":"Imam SK. Advancements in cancer therapy with alpha-emitters: a review. Int J Radiat Oncol Biol Phys. 2001;51(1):271\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2117_CR8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","volume":"59","author":"S Poty","year":"2018","unstructured":"Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. \u03b1-Emitters for radiotherapy: from basic radiochemistry to clinical studies\u2014part 1. J Nucl Med. 2018;59(6):878\u201384.","journal-title":"J Nucl Med"},{"issue":"6","key":"2117_CR9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.cdd.4401047","volume":"9","author":"MR McDevitt","year":"2002","unstructured":"McDevitt MR, Scheinberg DA. Ac-225 and her daughters: the many faces of Shiva. Cell Death Differ. 2002;9(6):593\u20134.","journal-title":"Cell Death Differ"},{"issue":"12","key":"2117_CR10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941\u20134.","journal-title":"J Nucl Med"},{"issue":"3","key":"2117_CR11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with (225)Actinium and (213)Bismuth. Curr Radiopharm. 2018;11(3):200\u20138.","journal-title":"Curr Radiopharm"},{"issue":"4 Suppl 1","key":"2117_CR12","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jmir.2019.07.007","volume":"50","author":"G Sgouros","year":"2019","unstructured":"Sgouros G. The case for dosimetry in alpha-emitter therapy. J Med Imaging Radiat Sci. 2019;50(4 Suppl 1):S45\u20136.","journal-title":"J Med Imaging Radiat Sci"},{"key":"2117_CR13","doi-asserted-by":"publisher","unstructured":"Zitzmann-Kolbe S, Remde Y, Moen I, Madas B, M\u00e1zik L, Suurs F, et al. Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225\/Francium-221 radionuclide generator set-up. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07427-4.","DOI":"10.1007\/s00259-025-07427-4"},{"issue":"Suppl 10","key":"2117_CR14","first-page":"S13","volume":"6 Suppl 10","author":"SS Chang","year":"2004","unstructured":"Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6 Suppl 10(Suppl 10):S13\u20138.","journal-title":"Rev Urol"},{"issue":"1","key":"2117_CR15","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2117_CR16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apm.12195","volume":"122","author":"AG Wernicke","year":"2014","unstructured":"Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KS, Liu H, et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS. 2014;122(6):482\u20139.","journal-title":"APMIS"},{"issue":"2","key":"2117_CR17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","volume":"48","author":"GL Wright Jr.","year":"1996","unstructured":"Wright GL Jr., Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326\u201334.","journal-title":"Urology"},{"issue":"7","key":"2117_CR18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","volume":"59","author":"DS O'Keefe","year":"2018","unstructured":"O\u2019Keefe DS, Bacich DJ, Huang SS, Heston WDW. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl Med. 2018;59(7):1007\u201313.","journal-title":"J Nucl Med"},{"issue":"5","key":"2117_CR19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59(5):795\u2013802.","journal-title":"J Nucl Med"},{"issue":"1","key":"2117_CR20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2967\/jnumed.119.229229","volume":"61","author":"M Sathekge","year":"2020","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving (225)Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61(1):62\u20139.","journal-title":"J Nucl Med"},{"issue":"5","key":"2117_CR21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","volume":"62","author":"MJ Zacherl","year":"2021","unstructured":"Zacherl MJ, Gildehaus FJ, Mittlmeier L, Boning G, Gosewisch A, Wenter V, et al. First clinical results for PSMA-targeted alpha-therapy using (225)Ac-PSMA-I&T in advanced-mCRPC patients. J Nucl Med. 2021;62(5):669\u201374.","journal-title":"J Nucl Med"},{"issue":"2","key":"2117_CR22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):175\u201383.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2117_CR23","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1007\/s00259-023-06340-y","volume":"50","author":"S Ballal","year":"2023","unstructured":"Ballal S, Yadav MP, Satapathy S, Raju S, Tripathi M, Damle NA, et al. Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study. Eur J Nucl Med Mol Imaging. 2023;50(12):3777\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2117_CR24","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","volume":"49","author":"IO Lawal","year":"2022","unstructured":"Lawal IO, Morgenstern A, Vorster M, Knoesen O, Mahapane J, Hlongwa KN, et al. Hematologic toxicity profile and efficacy of [(225)Ac]Ac-PSMA-617 alpha-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(10):3581\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2117_CR25","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2967\/jnumed.121.263618","volume":"63","author":"M Sathekge","year":"2022","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. mCRPC patients receiving (225)Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting: response to treatment and survival analysis. J Nucl Med. 2022;63(10):1496\u2013502.","journal-title":"J Nucl Med"},{"issue":"7","key":"2117_CR26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2967\/jnumed.123.267206","volume":"65","author":"H Rathke","year":"2024","unstructured":"Rathke H, Winter E, Bruchertseifer F, Rohrich M, Giesel FL, Haberkorn U, et al. Deescalated (225)Ac-PSMA-617 versus (177)Lu\/(225)Ac-PSMA-617 cocktail therapy: a single-center retrospective analysis of 233 patients. J Nucl Med. 2024;65(7):1057\u201363.","journal-title":"J Nucl Med"},{"issue":"3","key":"2117_CR27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. (225)Ac-PSMA-617\/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47(3):721\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2117_CR28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13550-016-0164-0","volume":"6","author":"EK Fung","year":"2016","unstructured":"Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, et al. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Res. 2016;6(1):7.","journal-title":"EJNMMI Res"},{"issue":"3","key":"2117_CR29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11307-008-0185-9","volume":"11","author":"MH Pan","year":"2009","unstructured":"Pan MH, Gao DW, Feng J, He J, Seo Y, Tedesco J, et al. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy. Mol Imaging Biol. 2009;11(3):159\u201366.","journal-title":"Mol Imaging Biol"},{"issue":"15","key":"2117_CR30","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","volume":"125","author":"ST Tagawa","year":"2019","unstructured":"Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, et al. Phase 1\/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019;125(15):2561\u20139.","journal-title":"Cancer"},{"issue":"18","key":"2117_CR31","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182\u201391.","journal-title":"Clin Cancer Res"},{"key":"2117_CR32","doi-asserted-by":"crossref","first-page":"CT143","DOI":"10.1158\/1538-7445.AM2022-CT143","volume":"82","author":"ST Tagawa","year":"2022","unstructured":"Tagawa ST, Fung E, Niaz MO, Bissassar M, Singh S, Patel A, Tan A, Zuloaga JM, Castellanos SH, Nauseef JT, Molina A, Sternberg C, Nanus DM, Osborne J, Bander NH. Abstract CT143: Results of combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody 225Ac-J591 and beta-radiolabeled ligand 177Lu-PSMA I&T: preclinical and initial phase 1 clinical data in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Res. 2022;82:CT143.","journal-title":"Cancer Res"},{"issue":"2","key":"2117_CR33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5603\/NMR.2016.0022","volume":"19","author":"J Hankus","year":"2016","unstructured":"Hankus J, Tomaszewska R. Neuroendocrine neoplasms and somatostatin receptor subtypes expression. Nucl Med Rev Cent East Eur. 2016;19(2):111\u20137.","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"7","key":"2117_CR34","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","volume":"28","author":"JC Reubi","year":"2001","unstructured":"Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1\u2013sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28(7):836\u201346.","journal-title":"Eur J Nucl Med"},{"issue":"2","key":"2117_CR35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0006-291X(80)91415-1","volume":"96","author":"P B\u00f6hlen","year":"1980","unstructured":"B\u00f6hlen P, Brazeau P, Benoit R, Ling N, Esch F, Guillemin R. Isolation and amino acid composition of two somatostatin-like peptides from ovine hypothalamus: somatostatin-28 and somatostatin-25. Biochem Biophys Res Commun. 1980;96(2):725\u201334.","journal-title":"Biochem Biophys Res Commun"},{"key":"2117_CR36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","volume":"152","author":"U Rai","year":"2015","unstructured":"Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: current view and potential applications. Pharmacol Ther. 2015;152:98\u2013110.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2117_CR37","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.clgc.2016.10.012","volume":"15","author":"MH Khorrami","year":"2017","unstructured":"Khorrami MH, Javid A, Izadpanahi MH, Alizadeh F, Zargham M, Khorrami F. Efficacy of long-acting octreotide on reducing mucus production in patients with ileal neobladder. Clin Genitourin Cancer. 2017;15(1):e9\u201313.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2117_CR38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"2117_CR39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.semnuclmed.2019.06.002","volume":"49","author":"J Zhang","year":"2019","unstructured":"Zhang J, Singh A, Kulkarni HR, Schuchardt C, Muller D, Wester HJ, et al. From bench to bedside-the Bad Berka experience with first-in-human studies. Semin Nucl Med. 2019;49(5):422\u201337.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"2117_CR40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","volume":"49","author":"C Kratochwil","year":"2021","unstructured":"Kratochwil C, Apostolidis L, Rathke H, Apostolidis C, Bicu F, Bruchertseifer F, et al. Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. Eur J Nucl Med Mol Imaging. 2021;49(1):54\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2117_CR41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","volume":"47","author":"S Ballal","year":"2020","unstructured":"Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47(4):934\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2117_CR42","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","volume":"49","author":"MP Yadav","year":"2022","unstructured":"Yadav MP, Ballal S, Sahoo RK, Bal C. Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur J Nucl Med Mol Imaging. 2022;49(5):1595\u2013606.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2117_CR43","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1159\/000533198","volume":"16","author":"A Krocher","year":"2023","unstructured":"Krocher A, Folprecht G, Winzer R, Sergon M, Bornhauser M, Kotzerke J, et al. Successful combination of Olaparib and (225)Ac-Dotatate in a patient with neuroendocrine tumor G3 and BRCA mutation. Case Rep Oncol. 2023;16(1):1166\u201371.","journal-title":"Case Rep Oncol"},{"issue":"1","key":"2117_CR44","first-page":"101","volume":"50","author":"T Speicher","year":"2025","unstructured":"Speicher T, Burgard C, Bastian M, Rosar F, Bartholoma M, Maus S, et al. First successful in-human application of 225Ac-DOTA-LM3 mono-PRRT for the treatment of an otherwise therapy-resistant neuroendocrine tumor (NET G3). Clin Nucl Med. 2025;50(1):101\u20132.","journal-title":"Clin Nucl Med"},{"key":"2117_CR45","doi-asserted-by":"publisher","unstructured":"Ballal S, Yadav MP, Tripathi M, Sahoo RK, Bal C. Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant (225)Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study. J Nucl Med. 2023;64(2):211\u2013218. https:\/\/doi.org\/10.2967\/jnumed.122.264043.","DOI":"10.2967\/jnumed.122.264043"},{"issue":"1","key":"2117_CR46","doi-asserted-by":"crossref","first-page":"e233408","DOI":"10.1148\/radiol.233408","volume":"312","author":"GA Ulaner","year":"2024","unstructured":"Ulaner GA, VanderMolen LA, Li G, Ferreira D. Dotatate PET\/CT and (225)Ac-Dotatate therapy for somatostatin receptor-expressing metastatic breast cancer. Radiology. 2024;312(1):e233408.","journal-title":"Radiology"},{"issue":"11","key":"2117_CR47","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1007\/s00259-021-05350-y","volume":"48","author":"L Krolicki","year":"2021","unstructured":"Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kulinski R, et al. Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma\u2014safety and efficacy. Eur J Nucl Med Mol Imaging. 2021;48(11):3595\u2013605.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2117_CR48","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","volume":"28","author":"TL Rosenblat","year":"2022","unstructured":"Rosenblat TL, McDevitt MR, Carrasquillo JA, Pandit-Taskar N, Frattini MG, Maslak PG, et al. Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator Actinium-225-Lintuzumab. Clin Cancer Res. 2022;28(10):2030\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2117_CR49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","volume":"8","author":"RM de Kruijff","year":"2015","unstructured":"de Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha radionuclide therapy\u2014how to deal with recoiling daughters? Pharmaceuticals (Basel). 2015;8(2):321\u201336.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"2117_CR50","first-page":"1508","volume":"42","author":"MR Zalutsky","year":"2001","unstructured":"Zalutsky MR, Zhao XG, Alston KL, Bigner D. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. J Nucl Med. 2001;42(10):1508\u201315.","journal-title":"J Nucl Med"},{"issue":"3","key":"2117_CR51","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.apradiso.2004.06.013","volume":"62","author":"C Apostolidis","year":"2005","unstructured":"Apostolidis C, Molinet R, McGinley J, Abbas K, M\u00f6llenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot. 2005;62(3):383\u20137.","journal-title":"Appl Radiat Isot"},{"issue":"2","key":"2117_CR52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.semnuclmed.2020.02.003","volume":"50","author":"A Morgenstern","year":"2020","unstructured":"Morgenstern A, Apostolidis C, Bruchertseifer F. Supply and clinical application of Actinium-225 and Bismuth-213. Semin Nucl Med. 2020;50(2):119\u201323.","journal-title":"Semin Nucl Med"},{"issue":"7","key":"2117_CR53","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","volume":"52","author":"HH Tran","year":"2025","unstructured":"Tran HH, Yamaguchi A, Manning HC. Radiotheranostic landscape: a review of clinical and preclinical development. Eur J Nucl Med Mol Imaging. 2025;52(7):2685\u2013709.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2117_CR54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40658-024-00635-1","volume":"11","author":"M Tulik","year":"2024","unstructured":"Tulik M, Kulinski R, Tabor Z, Brzozowska B, Laba P, Bruchertseifer F, et al. Quantitative SPECT\/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas. EJNMMI Phys. 2024;11(1):41.","journal-title":"EJNMMI Phys"},{"issue":"8","key":"2117_CR55","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","volume":"51","author":"G Liubchenko","year":"2024","unstructured":"Liubchenko G, B\u00f6ning G, Zacherl M, Rumiantcev M, Unterrainer LM, Gildehaus FJ, et al. Image-based dosimetry for [(225)Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics. Eur J Nucl Med Mol Imaging. 2024;51(8):2504\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"25","key":"2117_CR56","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1073\/pnas.251524798","volume":"98","author":"H Zhou","year":"2001","unstructured":"Zhou H, Suzuki M, Randers-Pehrson G, Vannais D, Chen G, Trosko JE, et al. Radiation risk to low fluences of alpha particles may be greater than we thought. Proc Natl Acad Sci U S A. 2001;98(25):14410\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2117_CR57","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41391-021-00349-w","volume":"24","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Sood A, Das CK, Mittal BR. Evolving role of (225)Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24(3):880\u201390.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"2117_CR58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen RS, Buteau JP, Jackson P, Mitchell C, Oon SF, Alghazo O, et al. Administering [(177)Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study. Eur Urol. 2024;85(3):217\u201326.","journal-title":"Eur Urol"},{"issue":"10","key":"2117_CR59","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58(10):1624\u201331.","journal-title":"J Nucl Med"},{"key":"2117_CR60","doi-asserted-by":"publisher","unstructured":"Medeiros RBd, Grigolon MV, Ara\u00fajo TP, Srougi M. Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report. Braz J Oncol. 2019;15(continuous publication). https:\/\/doi.org\/10.5935\/2526-8732.20190002.","DOI":"10.5935\/2526-8732.20190002"},{"issue":"8","key":"2117_CR61","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s00259-019-04354-z","volume":"46","author":"MM Sathekge","year":"2019","unstructured":"Sathekge MM, Bruchertseifer F, Lawal IO, Vorster M, Knoesen O, Lengana T, et al. Treatment of brain metastases of castration-resistant prostate cancer with (225)Ac-PSMA-617. Eur J Nucl Med Mol Imaging. 2019;46(8):1756\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2117_CR62","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","volume":"46","author":"M Sathekge","year":"2019","unstructured":"Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. (225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46(1):129\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2117_CR63","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79(3):343\u201350.","journal-title":"Eur Urol"},{"issue":"4","key":"2117_CR64","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00259-020-05023-2","volume":"48","author":"H Ilhan","year":"2021","unstructured":"Ilhan H, Gosewisch A, B\u00f6ning G, V\u00f6lter F, Zacherl M, Unterrainer M, et al. Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC. Eur J Nucl Med Mol Imaging. 2021;48(4):1262\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2117_CR65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00259-020-04875-y","volume":"48","author":"H Rathke","year":"2021","unstructured":"Rathke H, Bruchertseifer F, Kratochwil C, Keller H, Giesel FL, Apostolidis C, et al. First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT. Eur J Nucl Med Mol Imaging. 2021;48(1):311\u20132.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2117_CR66","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/ijnm.IJNM_130_20","volume":"35","author":"S Satapathy","year":"2020","unstructured":"Satapathy S, Mittal BR, Sood A, Das CK, Singh SK, Mavuduru RS, et al. Health-related quality-of-life outcomes with Actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer. Indian J Nucl Med. 2020;35(4):299\u2013304.","journal-title":"Indian J Nucl Med"},{"issue":"10","key":"2117_CR67","doi-asserted-by":"crossref","first-page":"729.e7","DOI":"10.1016\/j.urolonc.2020.12.002","volume":"39","author":"MJ van der Doelen","year":"2021","unstructured":"van der Doelen MJ, Mehra N, van Oort IM, Looijen-Salamon MG, Janssen MJR, Custers JAE, et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with (225)Ac-PSMA-617 targeted alpha-radiation therapy. Urol Oncol. 2021;39(10):729.e7\u2013.e16.","journal-title":"Urol Oncol"},{"issue":"20","key":"2117_CR68","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","volume":"10","author":"MP Yadav","year":"2020","unstructured":"Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020;10(20):9364\u201377.","journal-title":"Theranostics"},{"key":"2117_CR69","first-page":"100038","volume":"3","author":"LC Maserumule","year":"2021","unstructured":"Maserumule LC, Mokoala KMG, Hlongwa KN, Ndlovu H, Reed JD, Ismail A, et al. Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: a case report. Curr Probl Cancer Case Rep. 2021;3:100038.","journal-title":"Curr Probl Cancer Case Rep"},{"issue":"3","key":"2117_CR70","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ekir.2020.12.006","volume":"6","author":"K Pelletier","year":"2021","unstructured":"Pelletier K, Cote G, Fallah-Rad N, John R, Kitchlu A. CKD after 225Ac-PSMA617 therapy in patients with metastatic prostate cancer. Kidney Int Rep. 2021;6(3):853\u20136.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"2117_CR71","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.7150\/thno.56211","volume":"11","author":"F Rosar","year":"2021","unstructured":"Rosar F, Hau F, Bartholoma M, Maus S, Stemler T, Linxweiler J, et al. Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617\/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy. Theranostics. 2021;11(9):4050\u201360.","journal-title":"Theranostics"},{"key":"2117_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050722","author":"F Rosar","year":"2021","unstructured":"Rosar F, Krause J, Bartholoma M, Maus S, Stemler T, Hierlmeier I, et al. Efficacy and safety of [(225)Ac]Ac-PSMA-617 augmented [(177)Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13050722.","journal-title":"Pharmaceutics"},{"issue":"12","key":"2117_CR73","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/RLU.0000000000003925","volume":"46","author":"Y Sanli","year":"2021","unstructured":"Sanli Y, Kuyumcu S, Simsek DH, Buyukkaya F, Civan C, Isik EG, et al. 225Ac-prostate-specific membrane antigen therapy for castration-resistant prostate cancer: a single-center experience. Clin Nucl Med. 2021;46(12):943\u201351.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"2117_CR74","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s12149-021-01617-4","volume":"35","author":"I Sen","year":"2021","unstructured":"Sen I, Thakral P, Tiwari P, Pant V, Das SS, Manda D, et al. Therapeutic efficacy of (225)Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy. Ann Nucl Med. 2021;35(7):794\u2013810.","journal-title":"Ann Nucl Med"},{"issue":"7","key":"2117_CR75","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s00259-023-06165-9","volume":"50","author":"M Sathekge","year":"2023","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Mokoala K, Reed J, et al. (225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Eur J Nucl Med Mol Imaging. 2023;50(7):2210\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2117_CR76","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","volume":"42","author":"ST Tagawa","year":"2024","unstructured":"Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, et al. Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of (225)Ac-J591. J Clin Oncol. 2024;42(7):842\u201351.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 3","key":"2117_CR77","first-page":"1232","volume":"56","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Bruchertseifer F, Giesel F, Apostolidis C, Haberkorn U, Morgenstern A. Ac-225-DOTATOC\u2014an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med. 2015;56(Suppl. 3):1232.","journal-title":"J Nucl Med"},{"issue":"11","key":"2117_CR78","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1007\/s00259-020-04725-x","volume":"47","author":"M Ocak","year":"2020","unstructured":"Ocak M, Toklu T, Demirci E, Sel\u00e7uk N, Kabasakal L. Post-therapy imaging of (225)Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. Eur J Nucl Med Mol Imaging. 2020;47(11):2711\u20132.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2117_CR79","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijnm.IJNM_58_20","volume":"35","author":"KK Kamaleshwaran","year":"2020","unstructured":"Kamaleshwaran KK, Suneelkumar M, Madhusairam R, Radhakrishnan EK, Arunpandiyan S, Arnold VJ. Whole-body and single-photon emission computed tomography\/computed tomography postpeptide receptor alpha radionuclide therapy images of Actinium 225-tetraazacyclododecanetetraacetic acid-octreotide as a primary modality of treatment in a patient with advanced rectal neuroendocrine tumor with metastases. Indian J Nucl Med. 2020;35(3):226\u20138.","journal-title":"Indian J Nucl Med"},{"issue":"3","key":"2117_CR80","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RLU.0000000000002915","volume":"45","author":"J Zhang","year":"2020","unstructured":"Zhang J, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy using 225Ac-DOTATOC achieves partial remission in a patient with progressive neuroendocrine liver metastases after repeated beta-emitter peptide receptor radionuclide therapy. Clin Nucl Med. 2020;45(3):241\u20133.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"2117_CR81","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/RLU.0000000000003792","volume":"46","author":"J Zhang","year":"2021","unstructured":"Zhang J, Kulkarni HR, Baum RP. 225Ac-DOTATOC-targeted somatostatin receptor alpha-therapy in a patient with metastatic neuroendocrine tumor of the thymus, refractory to beta-radiation. Clin Nucl Med. 2021;46(12):1030\u20131.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2117_CR82","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1097\/RLU.0000000000003823","volume":"47","author":"S Satapathy","year":"2022","unstructured":"Satapathy S, Sood A, Das CK, Kavanal AJ, Mittal BR. Alpha before beta: exceptional response to first-line 225Ac-DOTATATE in a patient of metastatic neuroendocrine tumor with extensive skeletal involvement. Clin Nucl Med. 2022;47(2):e156\u20137.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2117_CR83","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1097\/RLU.0000000000003893","volume":"47","author":"AJ Kavanal","year":"2022","unstructured":"Kavanal AJ, Satapathy S, Sood A, Khosla D, Mittal BR. Subclinical hypothyroidism after 225Ac-DOTATATE therapy in a case of metastatic neuroendocrine tumor: unknown adverse effect of PRRT. Clin Nucl Med. 2022;47(2):e184\u20136.","journal-title":"Clin Nucl Med"},{"key":"2117_CR84","doi-asserted-by":"publisher","first-page":"16275","DOI":"10.20452\/pamw.16275","volume":"132","author":"T Budlewski","year":"2022","unstructured":"Budlewski T, Kr\u00f3l ZJ, Bruchertseifer F, et al. Innovative radioisotope therapy for patients with neuroendocrine tumors using an alpha (225Ac) emitter labeled somatostatin analog: octreotate. A promising new treatment for advanced progressive neuroendocrine neoplasms. Pol Arch Intern Med. 2022;132:16275. https:\/\/doi.org\/10.20452\/pamw.16275.","journal-title":"Pol Arch Intern Med"},{"issue":"2","key":"2117_CR85","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4274\/mirt.galenos.2022.64497","volume":"31","author":"N Alan Selcuk","year":"2022","unstructured":"Alan Selcuk N, Demirci E, Ocak M, Toklu T, Ergen S, Kabasakal L. Almost complete response with a single administration (225)Ac-DOTATATE in a patient with a metastatic neuroendocrine tumor of unknown primary. Mol Imaging Radionucl Ther. 2022;31(2):139\u201341.","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"3","key":"2117_CR86","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4274\/mirt.galenos.2023.38258","volume":"32","author":"E Demirci","year":"2023","unstructured":"Demirci E, Alan Selcuk N, Beydagi G, Ocak M, Toklu T, Akcay K, et al. Initial findings on the use of [(225)Ac]Ac-DOTATATE therapy as a theranostic application in patients with neuroendocrine tumors. Mol Imaging Radionucl Ther. 2023;32(3):226\u201332.","journal-title":"Mol Imaging Radionucl Ther"},{"key":"2117_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14090907","author":"E Perrone","year":"2024","unstructured":"Perrone E, Ghai K, Eismant A, Andreassen M, Langer SW, Knigge U, et al. Impressive response to TANDEM peptide receptor radionuclide therapy with (177)Lu\/(225)AcDOTA-LM3 somatostatin receptor antagonist in a patient with therapy-refractory, rapidly progressive neuroendocrine neoplasm of the pancreas. Diagnostics. 2024. https:\/\/doi.org\/10.3390\/diagnostics14090907.","journal-title":"Diagnostics"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02117-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02117-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02117-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:30:52Z","timestamp":1761571852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02117-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":87,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2117"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02117-5","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author declared that no conflicts of interest exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}